- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 3 Aug 2026
- Managers listing it
- 29
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 15 listed it in both
- Shares listed
- 38,105,818
- combined, among listed positions
- Reported value
- $5.5bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 14 buyers (opened or added shares) and 19 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +1,738,627.
Managers listing EMR in Q2 2026
29 of 29 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 8,740,297 shares now+5,940,147
- Point72 Asset Management LPnew position · 557,706 shares now+557,706
- Walleye Capital LLCexisting position · 341,280 shares now+334,226
- ExodusPoint Capital Management LPexisting position · 91,613 shares now+86,198
- AQR Capital Management LLCexisting position · 208,508 shares now+46,915
Reductions
- Invesco Ltdexisting position · 6,978,387 shares now-1,369,414
- Wellington Management Group LLPexisting position · 8,464,091 shares now-1,153,964
- Citadel Advisors LLCexisting position · 453,070 shares now-440,127
- Janus Henderson Group Ltdexisting position · 1,819,736 shares now-387,971
- Squarepoint Ops LLCexisting position · 26,668 shares now-324,671
New positions and exits
New (4)
Exited (4)
- Capital Research Global Investorswas $93m
- Arrowstreet Capital LPwas $6.6m
- Verition Fund Management LLCwas $4.3m
- Schonfeld Strategic Advisors LLCwas $5k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 14 | $2.6bn | n.a. | n.a. |
| Q3 2013 | 13 | $3.5bn | n.a. | n.a. |
| Q4 2013 | 16 | $3.8bn | n.a. | n.a. |
| Q1 2014 | 18 | $3.2bn | n.a. | n.a. |
| Q2 2014 | 22 | $3.1bn | n.a. | n.a. |
| Q3 2014 | 18 | $2.7bn | n.a. | n.a. |
| Q4 2014 | 17 | $2.2bn | n.a. | n.a. |
| Q1 2015 | 17 | $2.0bn | n.a. | n.a. |
| Q2 2015 | 20 | $2.5bn | n.a. | n.a. |
| Q3 2015 | 18 | $2.3bn | n.a. | n.a. |
| Q4 2015 | 16 | $2.3bn | n.a. | n.a. |
| Q1 2016 | 16 | $2.7bn | n.a. | n.a. |
| Q2 2016 | 13 | $2.7bn | n.a. | n.a. |
| Q3 2016 | 17 | $3.2bn | n.a. | n.a. |
| Q4 2016 | 16 | $3.0bn | n.a. | n.a. |
| Q1 2017 | 17 | $2.4bn | n.a. | n.a. |
| Q2 2017 | 14 | $2.3bn | n.a. | n.a. |
| Q3 2017 | 14 | $2.4bn | n.a. | n.a. |
| Q4 2017 | 18 | $2.9bn | n.a. | n.a. |
| Q1 2018 | 17 | $2.6bn | n.a. | n.a. |
| Q2 2018 | 17 | $2.6bn | n.a. | n.a. |
| Q3 2018 | 16 | $2.9bn | n.a. | n.a. |
| Q4 2018 | 20 | $2.9bn | n.a. | n.a. |
| Q1 2019 | 20 | $2.6bn | n.a. | n.a. |
| Q2 2019 | 15 | $2.5bn | n.a. | n.a. |
| Q3 2019 | 16 | $2.2bn | n.a. | n.a. |
| Q4 2019 | 23 | $3.4bn | n.a. | n.a. |
| Q1 2020 | 17 | $2.0bn | n.a. | n.a. |
| Q2 2020 | 16 | $2.4bn | n.a. | n.a. |
| Q3 2020 | 18 | $2.4bn | n.a. | n.a. |
| Q4 2020 | 18 | $3.5bn | n.a. | n.a. |
| Q1 2021 | 16 | $3.8bn | n.a. | n.a. |
| Q2 2021 | 20 | $4.6bn | n.a. | n.a. |
| Q3 2021 | 17 | $4.4bn | n.a. | n.a. |
| Q4 2021 | 20 | $3.7bn | n.a. | n.a. |
| Q1 2022 | 21 | $3.3bn | n.a. | n.a. |
| Q2 2022 | 24 | $2.8bn | n.a. | n.a. |
| Q3 2022 | 28 | $3.1bn | n.a. | n.a. |
| Q4 2022 | 21 | $4.3bn | n.a. | n.a. |
| Q1 2023 | 26 | $4.3bn | n.a. | n.a. |
| Q2 2023 | 24 | $4.1bn | n.a. | n.a. |
| Q3 2023 | 20 | $3.8bn | n.a. | n.a. |
| Q4 2023 | 18 | $3.5bn | 10 | 8 |
| Q1 2024 | 19 | $4.1bn | 11 | 8 |
| Q2 2024 | 24 | $4.3bn | 15 | 8 |
| Q3 2024 | 14 | $3.8bn | 7 | 6 |
| Q4 2024 | 10 | $4.1bn | 4 | 9 |
| Q1 2025 | 11 | $4.0bn | 9 | 2 |
| Q2 2025 | 16 | $5.4bn | 12 | 4 |
| Q3 2025 | 13 | $4.7bn | 6 | 8 |
| Q4 2025 | 14 | $4.5bn | 16 | 16 |
| Q1 2026 | 16 | $4.6bn | 16 | 15 |
| Q2 2026 | 14 | $4.7bn | 14 | 19 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
EMR and GE →EMR and LRCX →EMR and GEV →Choose a stock to compare with EMR →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own EMR, latest filings →Back to the 13F Explorer →